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ABSTRACT
Oncogenesis in breast cancer often requires the
overexpression of the nuclear receptor coactivator
AIB1/SRC-3 acting in conjunction with estrogen
receptor-a (ERa). Phosphorylation of both ERa and
AIB1 has been shown to have profound effects on
their functions. In addition, proteasome-mediated
degradation plays a major role by regulating their
stability and activity. CK1d, a member of the ubiqui-
tous casein kinase-1 family, is implicated in the pro-
gression of breast cancer. In this study, we show
that both ERa and AIB1 are substrates for CK1d
in vitro, and identify a novel AIB1 phosphorylation
site (S601) targeted by CK1d, significant for the
co-activator function of AIB1. CK1d is able to inter-
act with ERa and AIB1 in vivo, while overexpression
of CK1d in breast cancer cells results in an
increased association of ERa with AIB1 as con-
firmed by co-immunoprecipitation assays from cell
lysates. Using an siRNA-based approach, luciferase
reporter assays and qRT-PCR, we observe that
silencing of CK1d leads to reduced ERa transcrip-
tional activity, despite increased ERa levels, simi-
larly to proteasome inhibition. We provide evidence
that AIB1 protein levels are reduced by CK1d silenc-
ing, in an estradiol-dependent manner; such desta-
bilization can be inhibited by pre-treatment with
the proteasome inhibitor MG132. We propose that
differing activities adopted by ERa and AIB1 as a
consequence of their interactions with and phos-
phorylation by CK1d, particularly AIB1 stabilization,
influence the transcriptional activity of ERa, and
therefore have a role in breast cancer development.
INTRODUCTION
Estrogen receptor alpha (ERa), a member of the nuclear
receptor (NR) superfamily of transcription factors, has
been one of the most successful therapeutic targets for
breast cancer (1). It contains 595 amino acids with a cen-
tral DNA-binding domain (DBD) and transcriptional
activation occurs through at least two distinct transactiva-
tion domains located in the amino-terminal A/B region
(AF-1) and the carboxy terminal E region of the receptor
(AF-2). The AF-1 domain is hormone-independent,
whereas the AF-2 domain is estrogen-dependent; both
AF domains are required for maximal ERa transcrip-
tionalactivity(2).Inadditiontobeingactivateduponbind-
ing estrogen, we and others have shown that ERa can
be activated by phosphorylation (3). Activation of ERa
is also coupled with its degradation by the ubiquitin-
proteasome pathway (4–6). Upon ligand binding, ERa
becomes ubiquitinated and is targeted by the 26S protea-
some for degradation (7). However, various direct or indi-
rect mechanisms have been described that can protect
ERa from proteasomal degradation and thereby modulate
its transcriptional activity including the involvement of the
Ampliﬁed in breast cancer-1 (AIB1) protein (8–10).
AIB1 (SRC-3/ACTR/pCIP/RAC3), a p160 co-activat-
ing oncogene overexpressed in diﬀerent types of cancer,
especially breast tumors (11), associates with and regulates
ERa transcriptional activity; AIB1 recruits co-factors
that possess histone acetyl-transferase activity and thus
increases ERa transcriptional activity through chromatin
remodeling (12–14). Interestingly, it has been reported
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ment of components of the ubiquitin-proteasome path-
way. Suppression of AIB1 leads to ERa stabilization in
the presence of estradiol (E2) and subsequent reduction of
ERa transcriptional activity (15). The activity of AIB1
is modulated post-transcriptionally by phosphorylation
which results in increased AIB1 degradation (16,17).
Recently, atypical protein kinase C (aPKC) has been
shown to stabilize AIB1 protein levels in cancer cells
(10), supporting the existence of an equilibrium of diﬀer-
ent kinases implicated in the promotion and prevention of
AIB1 degradation, so called dual kinase regulation.
Casein kinase 1 (CK1), a highly conserved Ser/Thr pro-
tein kinase family, is ubiquitously expressed in all eukary-
otic organisms (18,19) and alterations in the expression
and/or activity of CK1 have been observed in breast car-
cinomas (19,20). Among CK1 isoforms, CK1d is able to
phosphorylate a diversity of substrates, modulating their
activity and subcellular localization (19,21). As changes in
the activity of CK1d, or mutations of CK1d-speciﬁc phos-
phorylation sites within it’s substrates, contribute to dys-
regulation of various signaling pathways (19,22–25), we
wished to establish the role of CK1d in the regulation of
ERa activity.
Here, we observe that CK1d can interact with and phos-
phorylate both AIB1 and ERa in vitro. Furthermore,
overexpression of CK1d protein levels in MCF7 cells
enhanced the interactions between ERa and AIB1.
CK1d silencing results in decreased ERa transcriptional
activity even though paradoxically ERa levels appear
increased. Moreover, these results demonstrate that the
eﬀects of CK1d silencing on AIB1 can be rescued by pro-
teasomal inhibition, suggesting that phosphorylation of
AIB1 by CK1d protects it from degradation. Finally we
identify S601 in AIB1, a hitherto unidentiﬁed site, as the
main phosphorylation aa targeted by CK1d, which is
required for the activity of AIB1. These data herein, and
recent evidence regarding dual kinase regulation (10), sug-
gest a general mechanism by which the characteristics
of the AIB1–ERa partnership can be modulated by
CK1d-mediated phosphorylation.
MATERIALS AND METHODS
Chemicals and reagents
E2 was obtained from Sigma (Gillingham, UK) and
dissolved in ethanol; Charcoal-dextran stripped serum
(DSS) was obtained from Gemini (Bolnet, UK). The
cell-permeable proteasome inhibitor MG132 and the
kinase inhibitor IC261 were obtained from Merck
(Nottingham, UK). Rabbit polyclonal CK1d antibody
was from Santa Cruz (Heidelberg, Germany); mouse
monoclonal ERa, rabbit monoclonal anti-phosphoERa–
S118 and anti-b-actin mouse monoclonal antibodies
were purchased from Abcam (Cambridge, UK) and
Millipore (Southampton, UK) respectively. HRP (horse-
radish peroxidase)-conjugated goat anti-rabbit IgG and
goat anti-mouse IgG antibodies were from GE
Healthcare (Slough, UK).
Plasmids
The expression plasmid for yellow ﬂuorescent protein
(EYFP)–CK1d was constructed as follows. PCR ampliﬁ-
cation was carried out using mouse testis cDNA as a
template and the CK1d primers: 50-GGATCCATGGAG
CTGAGGGTCGGGACA-30,3 0-GGATCCTCAGTAGG
TGGTACGTCGTGG-50, which contain a BamH1
restriction site (underlined). The PCR product was then
cloned into the multiple cloning site of pcDNA3.1/V5-His-
TOPO vector (Invitrogen, Paisley, UK) and then sub-
cloned into the BamH1 site of pEYFP vector (BD
Biosciences Clontech, Heidelberg, Germany). The expres-
sion plasmid for human Flag-tagged AIB1 (pCMV-
Flag-AIB1) was generated as described previously (26).
The expression plasmids: (i) pSG5-ERa (27) and
(ii) pGEX4T–AIB1 (encompassing amino acids 582–800)
(26) were kind gifts from Professors Simak Ali and Bert
W. O’Malley respectively.
Site-directed mutagenesis
The expression plasmid pCMV-Flag-AIB1 baring a muta-
tion at aa S601A was generated using the QuikChange
site-directed mutagenesis kit according to manufacturer’s
instructions (Stratagene). The plasmid pCMV-Flag-AIB1
served as a template and the complementary primers used
were: 50-GACAAAGAAAGTAAGGAGGCCAGTGTT
GAGGGGGCAGAG-30 (sense) and 50-CTCTGCCCCC
TCAACACTGGCCTCCTTACTTTCTTTGTC-30 (anti-
sense). The plasmids pGEX4T–AIB1 aa 582–800 contain-
ing mutations at aas: S601A, S664A, T714A, S715A and
S794 of AIB1, were constructed using the plasmid
pGEX4T–AIB1 582–800 as a template and the following
complimentary primers: (i) S601A: 50-GACAAAGAA
AGTAAGGAGGCCAGTGTTGAGGGGGCAGAG-30
(sense) and 50-CTCTGCCCCCTCAACACTGGCCTCC
TTACTTTCTTTGTC-30 (antisense), (ii) S664A: 50-GT
CTCCTCCTCTACAGCTGG AGGAGTATCCTC-30
(sense) and 50-GAGGATACTCCTCCAGCTGTAGAG
GAGGAGAC-30 (antisense), (iii) T714A: 50-GACA CC
AGCAGTATAGCTTCTTGTGGGACGG-30 (sense)
and 50-CCGTCCCCACAAGAAGCTATACTGCTGGT
GTC-30 (antisense), (iv) S715A: 50-CCAGCAGTATAAC
TGCTTGTGGGGACGGAAATG-30 (sense) and 50-CAT
TTCCGTCCCCACAAGCAGTTATACTGCTGG-30
(antisense), (v) S794A: 50-GACAAGTGAAGAGGGAG
CTGGAGACTTGGATAATC-30 (sense) and 50- GATT
ATCCAAGTCTCCAGCTCCCTCTTCACTTGTC-30
(antisense).
Cellculture andtransfections
MCF7, T47D, MELN (28) and COS-1 cells were main-
tained in DMEM supplemented with 10% DSS, 1% peni-
cillin/streptomycin and 2% glutamine. HeLa cell line
expressing wild-type ERa has been described elsewhere
(29) (a kind gift from Dr Shapiro). All cells were incubated
at 378C in a humidiﬁed 5% CO2 atmosphere. MCF7 and
MELN cells were transfected with 5nM siRNA using
Hiperfect according to the manufacturer’s instructions
(Qiagen, Crawley, UK). Transient transfections of COS-1
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FuGENE 6 according to the manufacturer’s instructions
(Roche, Sussex, UK). Cells were maintained in phenol
red-free media with 5% charcoal-stripped serum 48h
before experimentation. The CK1d isoform was silenced
using two independent siRNAs, targeting the following
sequences: 50-ccggtct aggatcgaaatgtt-30 and 50-ctccctgacga
ttccactgta-30. At 48h (or 72h) post-transfection, cells were
treated with either vehicle (ethanol) or E2, and harvested
later (as indicated) for RNA or protein analyses.
RNA isolation andquantitative RT-PCR
Isolation of total RNA was performed using the RNeasy
kit (Qiagen). RNA (1mg) was reverse transcribed using
oligo (deoxythymidine) primers (Qiagen) and Super-
Script II reverse transcriptase (Invitrogen). Quantitative
RT-PCRs using the TaqMan mastermix (Applied Biosys-
tems) were performed on a 7900HT Thermocycler
(Applied Biosystems, Warrington, UK) using primers for
pS2, PR and GAPDH cDNAs, purchased from Applied
Biosystems.
Fireflyluciferase assay
MELN cells (0.5 10
6) were plated in 24-well plates in
medium containing DMEM/10% DSS for 24h, trans-
fected with CK1d siRNA for 48h and treated with E2
(10nM) or vehicle (ethanol) for 24h. The cells were
washed twice with PBS and lysed in 50ml/well luciferase
cell culture lysis reagent (Promega, Southampton, UK).
Luciferase assays were performed using the ﬁreﬂy lucifer-
ase assay system from Promega, according to the manu-
facturer’s instructions, and measured with a Top Count
NXT luminometer (Packard Biosciences, Beaconsﬁeld,
UK). All experiments were performed independently at
least three times, and results presented as the mean with
standard error of the mean error bars. Data are normal-
ized to the untreated sample, which was given a reference
value of one.
Westernblotting and SDS–PAGE
Whole cell lysates were prepared in NP40 lysis buﬀer
(50mM Tris–HCl, pH 8.0, 150mM NaCl, 10% (v/v) gly-
cerol, 1% NP40, 5mM dithiothreitol (DTT), 1mM
EDTA, 1mM EGTA, 50mM leupeptin and 30mg/ml apro-
tinin). For western blotting, extracts were clariﬁed by
centrifugation at 15000g for 20min at 48C and the pro-
tein concentration of the lysates was determined using
the bicinchoninic acid (BCA) protein assay (Pierce,
Cramlington, UK). Lysates were then boiled in 5 
sodium dodecyl sulfate (SDS) sample buﬀer (5min,
958C), subjected to 12.5% SDS–PAGE and blotted
on a Hybond C super nitrocellulose membrane (GE
Healthcare). Following this, the membranes were blocked
in TBS containing 0.1% (v/v) Tween20 and 5% (w/v) non-
fat milk for 1h, before probed overnight (O/N) with dif-
ferent antibodies in the same buﬀer, and washed exten-
sively in TBS/Tween. Immunocomplexes were detected
by incubation for 45min with HRP-conjugated goat
anti-rabbit IgG or goat anti-mouse IgG (1:1000 dilution),
followed by enhanced chemiluminescence detection (ECL)
(GE Healthcare). The intensity of bands were quantiﬁed
using Image J software (NIH, Bethesda, MD).
Immunoprecipitation
Cells lysates were cleared by centrifugation (15000rpm,
10min, 48C). Lysates containing equal amounts of pro-
teins were precleared with IgG bound to protein A or
G-agarose beads (Sigma) for 12h at 48C and immunopre-
cipitated with the speciﬁc primary antibody and protein A
or protein G-agarose overnight with gentle agitation.
The precipitates were then subjected to SDS–PAGE and
immunoblotting using phosphospeciﬁc primary antibodies
and horseradish peroxidase-labeled secondary antibodies.
In vitro kinase assays
In vitro kinase assays were carried out as described pre-
viously (23). ERa-substrates that were used were: (i) full-
length recombinant human ERa, (ii) GST-recombinant
human ERa fragment encompassing the AF1 transactiva-
tion domain and the DNA-binding domain (aa 1–280) and
(iii) GST-recombinant human ERa fragment encompass-
ing the ligand-binding domain (LBD) (aa 283–595).
AIB1-substrates were: (i) full-length puriﬁed AIB1 and
(ii) diﬀerent GST-recombinant human AIB1 fragments
encompassing the RID region, responsible for ligand-
dependent interaction with NRs (aa 582–800) (wt and
those containing mutations at the following AIB1 aas:
S601A, S664A, T714A, S715A and S794A). As a source
of enzyme activity we used GST-tagged recombinant
human CK1d protein (Invitrogen). Phosphorylated pro-
teins were resolved by SDS–PAGE and the protein
bands were visualized by autoradiography. Where indi-
cated, the phosphorylated protein bands were excised
and quantiﬁed by Cherenkov counting using LS-6500
scintillation counter (Beckman Coulter, San Francisco,
CA, USA).
Immunofluorescence
MCF-7 cells were grown on poly-D-lysine-coated glass
coverslips for 24h in DMEM/10% DSS. Next, cells
were transfected with CK1d siRNA or vehicle (ethanol)
for 48h and treated with E2 (10nM) for 24h. Cells were
then washed twice in PBS and ﬁxed in methanol for 15min
at 208C. Fixed cells were washed with PBS and blocked
with 0.2% gelatin in PBS for 1h, before incubating them
with AIB1 anti-rabbit antibody (1:300 in PBS) for 45min
at room temperature. After washing with PBS, coverslips
were incubated for 45min at RT with Alexa 488 secondary
antibody (Invitrogen). DNA was visualized by DAPI
staining. Cells were examined on an Axiovert-200 laser
scanning inverted microscope (Zeiss, Welwyn Garden
City, UK) equipped with a confocal imaging system.
Statistical analysis
Exploratory data analysis demonstrated that the distribu-
tions were often skewed with outliers. Shapiro–Wilks test
was used to test for normality (data were not normally
distributed) and between group comparisons were made
using the non parametric Mann–Whitney U-test.
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CK1dsilencing modulatesERatranscriptional activity and
decreases E2-inducedexpression ofERaregulated genes
To investigate the involvement of CK1d in E2-dependent
transcriptional activation of ERa, MELN cells (MCF7
cells, stably transfected with a luciferase reporter gene
under the control of an estrogen response element using
the b-globin promoter) were transfected with negative
control siRNA (CT siRNA) or CK1d siRNA (5nM), trea-
ted with 10nM E2 for 24h, and luciferase activities mea-
sured. Treatment with E2 alone resulted in a 20-fold
induction of luciferase activity. There were no eﬀects of
CT siRNA on the activity of ERa in this assay. However,
in the presence of CK1d siRNA the E2-dependent lucifer-
ase activity was decreased 35%, implying an association
of CK1d in E2-induced ERa activation (Figure 1A).
Quantitative real-time PCR (qRT-PCR) conﬁrmed
 80% reduced CK1d mRNA levels after siRNA treat-
ment (Figure 1B).
We next examined the eﬀects of CK1d silencing on
ER-regulated gene expression by performing qRT-PCR
for two well-known estrogen-induced genes (pS2 and
PR). Treatment of MCF7 cells with CK1d siRNA for
48h reduced expression of both pS2 and PR, by 55%
and 43%, respectively (Figure 1C and D). These results,
in conjunction with the luciferase assay performed in
MELN cells, conﬁrmed either a direct or indirect involve-
ment of CK1d in the regulation of ERa target gene expres-
sion. Use of 1mM IC261 (30), a small molecule inhibitor
preferentially inhibiting the CK1d and e isoforms, resulted
in a higher reduction of pS2 and PR expression (69% and
66%, respectively) (Figure 1E and F). This diﬀerence can
be explained by the fact that the use of siRNA knocked
down  80% of CK1d; therefore the lesser eﬀect on gene
expression after siRNA treatment, compared to IC261
treatment, is due to the residual CK1d. To establish
whether downregulation of ERa-targeted genes expression
is partly due to CK1d catalytic suppression, we trans-
fected MCF7 cells for 24h with an expression plasmid
encoding EYFP-CK1d. Overexpression of CK1d (con-
ﬁrmed by western blotting) resulted in a  2-fold increase
in E2-induced expression of pS2 (Figure 1G), demonstrat-
ing that the presence of CK1d regulates ERa target gene
expression.
ERa–S118is nottargeted forphosphorylation by CK1d
Since we have previously shown that phosphorylation at
S118 of ERa is implicated in regulation of transcriptional
activation (31,32), we analyzed the eﬀects of CK1d silenc-
ing on phosphorylation of ERa. MCF7 cells, untrans-
fected or transfected with either CT siRNA or CK1d
siRNA, were stimulated for 30min with 100nM E2 and
then probed for ERa phospho-S118. Short-term E2 treat-
ment induced ERa phosphorylation at S118 in both
untransfected and control siRNA-transfected cells
(Figure 2A). This phosphorylation was not suppressed
by CK1d siRNA, but was instead increased (Figure 2A
and B). Furthermore, the total ERa protein content was
also increased in the CK1d siRNA-treated cells.
Quantiﬁcation and comparison of the phospho-
S118:ERa ratio in treated and untreated MCF7 cells
implicated upregulation of ERa protein levels as cause
of the increase in observed ERa phospho-S118 phosphor-
ylation levels (Figure 2B).
In order to further validate that ERa–S118 is not phos-
phorylated by CK1d in vivo, we used a stably transfected
HeLa cell line expressing wild-type ERa (Figure 2C).
Compared with E2 treatment, CK1d siRNA failed to
reduce the phosphorylation of S118 in Hela-ERa cells
(Figure 2D and E). These results indicate that the involve-
ment of CK1d in the regulation of ERa transcriptional
activation is not mediated via phosphorylation at S118,
but could result from phosphorylation either at: (i) other
ERa site(s) or (ii) proteins that interact and modulate ERa
activity.
CK1dsilencing stabilizes ERaprotein levelsin breast
cancer cell lines
Next, we investigated protein levels of ERa following inhi-
bition of the proteasome in the presence of E2 (100nM).
Addition of MG132 (5mM), a cell permeable proteasome
inhibitor, prevented ERa degradation in E2-treated MCF7
(Figure 3A and B) and T47D breast cancer cells (Figure 3C
and D) Moreover, in the presence of E2, both CK1d silen-
cing and MG132 treatment elevated ERa levels, while
co-treatment resulted in further increases. Similar results
were obtained in MCF7 cells, using another independent
CK1d siRNA, ensuring that the data do not reﬂect oﬀ-
target eﬀects (Supplementary Figure 1A and B). Finally,
in order to investigate whether the observed CK1d silenc-
ing-related increase of ERa protein levels might be induced
by an increase of ERa gene transcription, we performed
qRT-PCR and examined the ERa mRNA expression
levels upon CK1d-siRNA treatment. Our results did not
reveal any signiﬁcant alteration of ERa mRNA following
CK1dRNAinterference (datanotshown).Taken together,
these data suggest that CK1d is implicated in the stabiliza-
tion of ERa in E2-stimulated cells, potentially through
direct or indirect phosphorylation events.
CK1dsilencing decreases AIB1 proteinlevels in the
presenceof E2
We have demonstrated that inhibition of CK1d leads to a
decrease in ERa transcriptional activity and a reduction
of E2-responsive gene expression, whilst stabilizing ERa
protein levels. Related ‘contradictory’ or apparently
‘paradoxical’ observations have been reported for AIB1
co-activator suppression (15), where AIB1 is necessary
for E2-induced ERa degradation, optimal binding of
ERa to target gene promoters and full ERa transcriptional
activity. Consequently, we investigated the eﬀects of CK1d
silencing on AIB1 protein levels. MCF7 cells were trans-
fected either with CT siRNA or CK1d siRNA in the
presence or absence of E2 (100nM), followed by immu-
noblotting using a mouse monoclonal AIB1 antibody.
Whereas in untreated, E2-treated and control siRNA-
treated cells the AIB1 protein levels remained unaﬀected,
treatment with CK1d siRNA followed by E2 stimulation
resulted in a 60% decrease of AIB1 protein levels
Nucleic Acids Research,2009, Vol.37, No. 9 3113Figure 1. CK1d silencing decreases the transcriptional activity of ERa and downregulates E2-induced expression of ERa target genes. (A) MELN
cells (5 10
4) were plated in 24-well plates in phenol red-free DMEM containing 10% stripped DSS. Cells were transfected with 5nM scrambled
siRNA (CT siRNA) or with 5nM CK1d siRNA for 48h and incubated with or without E2 (10nM) for 24h. ERE-dependent gene expression was
quantiﬁed by measuring luciferase activity, given as fold of control. Error bars represent SD of two experiments. (B) Quantitative real-time RT–PCR
validation of down-regulation of CK1d mRNA levels after treatment with 5nM siRNA. MCF7 cells (2 10
5) were plated in 6-well plates in phenol
red-free DMEM containing 10% DSS. Cells were transfected either with 5nM CT siRNA or with 5nM siRNA targeting CK1d and treated or not
(vehicle) with E2 (10nM) for 24h. Cells were harvested and total RNA was extracted and used to synthesize cDNA by reverse transcription, as
3114 Nucleic Acids Research, 2009, Vol. 37,No. 9(Figure 4A and B). Moreover, overexpression of CK1d in
MCF7 cells resulted in stabilization of AIB1 (data not
shown).
Since AIB1 can be degraded through the 26S protea-
some (as well as the REGg-mediated proteasome path-
way) we examined whether AIB1 downregulation could
be rescued by MG132. Use of MG132 rescued the CK1d
siRNA-mediated decrease of AIB1 in E2-treated MCF7
cells (Figure 4C and D) (similar results were obtained
using another independent CK1d siRNA). These results
imply an involvement of CK1d in the proteasome-
dependent regulation of AIB1 expression.
described in ‘Materials and Methods’ section. Gene expression of (C) pS2 and (D) PR was measured by quantitative real-time RT–PCR. MCF-7 cells
(2 10
5) were plated in 6-well plates in phenol red-free DMEM containing 10% DSS. Following, cells were incubated for 24h with 1mM of the
CK1d/e-speciﬁc inhibitor IC261 and treated or not (vehicle) with E2 (10nM) for 24h. Cells were harvested and total RNA was extracted and used to
synthesize cDNA by reverse transcription, as described in ‘Materials and Methods’ section. Gene expression of (E) pS2 and, (F) PR was measured by
quantitative real-time RT–PCR. Transfection of MCF7 cells with a (EYFP)-CK1d plasmid resulted in an increase of (G) pS2 expression. GAPDH
was used for normalisation. Error bars represent SD of two separate experiments, each in triplicate; changes observed throughout these experiments
were statistically signiﬁcant (P<0.05).
Figure 2. CK1d does not phosphorylate ERa at S118. (A) MCF7 cells (2 10
5) were plated in 6-well plates in phenol red-free DMEM containing
10% DSS. Cells were untransfected or transfected with 5nM CT siRNA or with 5nM CK1d siRNA for 72h and treated or not with E2 (100nM) for
45min. Cells were harvested, lysed and equal protein amounts were subjected to Western blotting analysis using the indicated antibodies. b-actin was
used as a control for sample loading. Immunoblot showing silencing of CK1d.( B) Quantitative analysis of ERa pS118, ERa protein levels and the
pS118:ERa ratio is given as fold of control. (C) Western blotting of the levels of ERa expressed in the stably transfected Hela-ERa cell line.
(D) Hela-ERa cells untransfected or transfected with 5nM CT siRNA or with 5nM CK1d siRNA for 72h were treated or not with E2 (100nM) for
45min. Cell extracts were immunoblotted. (E) Quantitative analysis of ERa phospho-S118, is given as fold of control. All data are representative of
results from two independent experiments. Error bars represent SD of two separate experiments in triplicate.
Nucleic Acids Research,2009, Vol.37, No. 9 3115TheeﬀectsofCK1dsilencingonAIB1proteinlevelswere
alsoinvestigatedbyIF,whereMCF7cells,untransfectedor
transfected with CK1d siRNA, were stimulated with E2,
and the subcellular localization of AIB1 was visualised
using the AIB1 antibody. Treatment with CK1d siRNA
resulted in a signiﬁcantly decrease in nuclear AIB1 com-
pared to untreated cells, in the presence of E2 (Figure 4E).
CK1dassociates withhuman ERaand AIB1 and regulates
theirinteractions
InordertoclarifywhetherERaandAIB1arephysiological
substrates for CK1d, we examined whether these proteins
can physically associate in vivo. COS-1 cells were transi-
ently transfected for 24h with expression plasmids encod-
ing for either: (i) ERa and CK1d or, (ii) AIB1 and CK1d,
following treatment with or without 100nM E2 for 30min.
Subsequently, the potential interactions between: (i) ERa–
CK1d and, (ii) AIB1-CK1d were assessed by immunopre-
cipitation of CK1d followed by analyses of the immune
complexes for the presence of ERa and AIB1 respectively.
An association of CK1d with ERa as well as with AIB1 in
the presence or absence of E2 was observed, although the
interaction was reduced in the absence of E2 (Figure 5A).
In addition, CK1d was able to co-precipitate with ERa
phosphorylatedatS118,suggestingthatitisabletointeract
with this form of ERa (Figure 5A).
TheabilityofCK1dtointeractwiththeERa–AIB1com-
plex, led us to examine whether CK1d is able to
inﬂuence the interactions between ERa and AIB1. To
address this issue, we overexpressed CK1d in MCF7 cells
for 24h, and performed co-immunoprecipitation experi-
ments following treatment with 100nM E2 for 30min.
Our results showed that increased CK1d protein levels
resulted in an increased ERa–AIB1 association, compared
to untransfected cells, in the presence of E2 (Figure 5B).
Overall, these data demonstrate that CK1d is involved
in the regulation of ERa–AIB1 interactions, critical for
the modulation of ERa transcriptional activity.
CK1dphosphorylates ERa inthe AF1-DBD domainand
AIB1atS601 in vitro
Since the phosphorylation status of ERa and AIB1 play
essential roles in their functions, we examined the ability
of CK1d to phosphorylate these proteins. We performed
in vitro kinase assays using the puriﬁed catalytic subunit of
CK1 as source of enzyme activity. As ERa-substrates we
Figure 3. CK1d silencing stabilizes ERa protein levels. (A) MCF7 or, (C) T47D cells were untransfected or transfected with 5nM CK1d siRNA for 72h.
MG132 (5mM) was added for 6h and following cells were treated with E2 (100nM) for 45min. Cell extracts were immunoblotted. Immunoblot showing
silencing of CK1d. Quantitative analysis of ERa protein levels with or without MG132 pretreatment in the presence of E2 in (B) MCF7 or, (D) T47D cells.
All data are representative of results from two independent experiments. Error bars represent SD of two separate experiments in triplicate.
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recombinant human ERa fragment encompassing the
AF1 transactivation domain and the DNA-binding
domain (aa 1–280) and (iii) GST-recombinant human
ERa fragment encompassing the LBD (aa 283–595)
(Figure 6A and B). As AIB1-substrates we used: (i) pur-
iﬁed full-length AIB1 and (ii) GST-recombinant human
AIB1 fragment encompassing the RID region, responsible
for ligand-dependent interaction with NRs (aa 582–800)
(Figure 6C and D).
We demonstrated that CK1d can phosphorylate ERa
in vitro, and its prospective phosphorylation target(s) are
located within the AF1-DBD area of ERa (Figure 6B).
Moreover, CK1d was able to phosphorylate full-length
AIB1 within aa 582–800 (Figure 6D). Use of additional
GST-fusion proteins containing fragments derived
from AIB1 (containing aa 1–321, aa 321–581 and aa
841–1081) were not phosphorylated by CK1d (our data
not shown and also shown by others) (26).
Bioinformatic sequence examination (http://scansite.
mit.edu) revealed several potential CK1d phosphorylation
sites in the AF1-DBD domain of ERa and in the region
between aa 582 and 800 of AIB1.
In order to determine the stoichiometry of AIB1 phos-
phorylation by CK1d, we performed in vitro time course
kinase assays using the GST-AIB1 fusion protein encom-
passing aa 582–800 as substrate and the puriﬁed catalytic
subunit of CK1 as enzyme. Our results demonstrated that
 1.6mol of phosphate were incorporated per mol of pro-
tein, implying the existence of at least one major aa in
AIB1 (within the region of aa 582–800) phosphorylated
by CK1 in vitro (Figure 6E). Subsequently, to identify the
exact phosphorylation site(s) of AIB1, we generated dif-
ferent GST-AIB1 aa 582–800 fusion proteins baring muta-
tions from S or T to A at various prospective aas (S601,
S664, T714, S715, S794) that could be phosphorylated by
CK1d. Our in vitro kinase assays clearly revealed that the
AIB1 residues (i) S664, (ii) T714 and (iii) S715 were
not targeted for phosphorylation by CK1 (Figure 6F).
Mutation of S794 to A resulted in a  10% reduction of
phosphorylation compared to the wild-type GST-AIB1 aa
582–800, whilst the degree of phosphorylation of
GST-AIB1 aa 582–800 S601A was less then 40% com-
pared with that of wild type GST-AIB1 aa 582–800
(Figure 6F). These results strongly suggest that the
major site of AIB1 phosphorylated by CK1d is S601.
Phosphorylation of S601 by CK1din vivoaffects the
co-activation function of AIB1
In order to examine the importance of S601 in relation to
CK1d phosphorylation in vivo, an AIB1 expression plas-
mid baring a mutation at S601A was generated (pCMV-
Flag-AIB1/S601A). Following this, the eﬀects of S601A
mutant on the ability of AIB1 to function as a transcrip-
tional co-activator was assessed by measuring the estro-
gen-dependent induction of endogenous pS2 mRNA levels
in MCF7 cells, after increasing or decreasing CK1d pro-
tein levels, respectively. In the presence of E2, transient
co-transfections of wt AIB1 and CK1d resulted in an
increase ( 60%) of pS2 gene expression levels, compared
to untransfected cells (Figure 7A), while a small increase
( 10%) of pS2 mRNA levels was observed after over-
expression of the AIB1/S601A mutant along with CK1d
(Figure 7A). To further establish that the observed
changes in the co-activation functions of AIB1 can be
attributed to phosphorylation of S601 by CK1d, MCF7
cells were treated with 1mM IC261 and pS2 mRNA levels
were quantiﬁed. In accordance with ‘our hypothesis’,
in the presence of E2 inhibition of CK1d led to decreased
activity of wt AIB1 to basal pS2 mRNA levels (Figure 7B)
compared to over-expression of both wt AIB1 and CK1d.
As expected, use of the IC261 inhibitor did not alter the
activity of AIB1/S601A mutant (Figure 7B). We conclude
that these functional data indicate that phospho-S601 res-
idue within the RID domain is necessary and suﬃcient for
AIB1 co-activation functions.
DISCUSSION
Protein phosphorylation, an essential post-translational
modiﬁcation, regulates protein functions including activ-
ity, stability, subcellular localization and interactions with
other proteins and substrates (33,34). Kinases are there-
fore considered key regulatory proteins and elucidation of
their roles in signaling pathways is essential (35). In the
present study, we have identiﬁed ERa and AIB1 as novel
substrates for CK1d in vitro that are able to interact in a
cellular context, proposing an involvement of CK1d in
regulating their interactions and functions. In addition,
we have identiﬁed S601 within AIB1 as a novel phosphor-
ylation site targeted by CK1d in vitro, while AIB1-S601A
mutant protein negatively inﬂuenced AIB1’s co-activation
function in ERa-dependent transcription. Furthermore,
using CK1d siRNA in MCF7 breast cancer cells, we
demonstrated that CK1d is required for full ERa tran-
scriptional activity and is involved in the regulation of
ERa protein levels in the presence of E2. Finally, we
have shown that suppression of CK1d results in protea-
some-mediated degradation of AIB1, in the presence of
E2, implying that CK1d phosphorylation protects AIB1
from proteolysis.
We examined the eﬀects of CK1d silencing on the tran-
scriptional activity of ERa and observed a 35% decrease
in the E2 response of an integrated ERE reporter gene.
Moreover, the eﬀects of CK1d silencing on the expression
levels of two endogenous estrogen-responsive genes, pS2
and PR, resulted in reductions of 55% and 43% respec-
tively when CK1d siRNA was used, while the reductions
were even higher (69% and 66%) in the presence of a
CK1d inhibitor (IC261). In contrast, overexpression of
CK1d resulted in a 2-fold increase in pS2 mRNA levels.
In vitro kinase assays using the CK1d as enzyme and dif-
ferent ERa fragments as substrates showed that CK1d
predominantly phosphorylates the AF1 domain of ERa.
Thus far, various kinases have been identiﬁed that can
phosphorylate the AF1 domain and thereby regulate
ERa activity (3,36). In this report, we identify a novel
involvement of CK1 as a direct and/or indirect regulator
of ERa transcriptional activity.
Nucleic Acids Research,2009, Vol.37, No. 9 3117Figure 4. CK1d silencing decreases AIB1 protein levels in the presence of E2. (A) MCF7 cells (2 10
5) were plated in 6-well plates in phenol red-free
DMEM containing 10% DSS. Cells were untransfected or transfected with 5nM CT siRNA or with 5nM CK1d siRNA for 72h and treated or not
with E2 (100nM) for 45min. Cells were harvested, lysed and equal protein amounts were subjected to western blotting using a speciﬁc AIB1 mouse
3118 Nucleic Acids Research, 2009, Vol. 37,No. 9Since phosphorylation of ERa S118 is correlated with
ERa activity, we next examined phospho-S118 levels in
MCF7 cells following CK1d silencing. Our results demon-
strate increased phospho-S118 levels that paradoxically
followed a CK1d siRNA-induced dependent increase in
total ERa. These data suggest that S118 is not phosphory-
lated by CK1d implicating other unidentiﬁed ERa site(s)
as targets for CK1d, which eventually could modulate the
activity of ERa. However, CK1d appears to be involved in
the regulation of ERa protein levels, as demonstrated in
two diﬀerent breast cancer cell lines (MCF7 and T47D)
after treatment with CK1d siRNA resulting in ERa stabi-
lization. It is well known that ERa protein turnover occurs
through the proteasome in a cyclic manner, dependent on
ligand binding, which ensures a stable and balanced cellu-
lar level of the receptor (6,37). Moreover, it has been
reported that the diﬀerential transcriptional activity
of ERa produced upon binding of diﬀerent synthetic
ligands (SERMs), correlates with the degradation rate of
ERa (38), with higher activities corresponding to faster
degradation. Various kinases and multiple agents that
activate or inhibit phosphorylation have been implicated
in modifying the proteasome-mediated stability of ERa
and consequently its activity (8,39–41). Taken together,
our data suggest that CK1 represents a new protein
kinase involved in the stabilization of ERa.
Additionally, several observations have linked the
recruitment of ERa co-factors with ligand-dependent deg-
radation of ERa. Particularly in the case of AIB1, it has
been shown that siRNA-mediated silencing of AIB1
results in ERa stabilization, but a loss in ERa activity.
This stabilization correlates with a reduction in
recruitment of components of the ubiquitin proteasome
machinery (15). Therefore, we have also examined the
eﬀects of CK1d silencing on AIB1 protein levels. CK1d
siRNA treatment in the presence of E2 produced a 60%
decrease in AIB1 protein levels, an eﬀect that was con-
ﬁrmed by IF, where the overall ﬂuorescent signal of
AIB1 was markedly weaker when cells were treated with
CK1d siRNA. The decrease in AIB1 levels was rescued by
proteasome inhibition, implicating CK1d in the regulation
of AIB1 proteasome-mediated degradation.
Our in vitro kinase assays demonstrated that AIB1, in
addition to ERa, can be a substrate for CK1d phosphor-
ylation. Use of an AIB1 GST-fusion protein revealed that
the prospective phosphorylation site(s) of AIB1 targeted
by CK1d are located within amino acids 582–800, which
encompass the RID domain of AIB1, required for inter-
actions with NRs. Time-course experiments revealed that
there is one major phosphorylation site for CK1 within aa
582–800 of AIB1. In vitro kinase assays using various
GST–AIB1 fusion proteins as substrates revealed that
CK1 mainly phosphorylates S601 in AIB1, a hitherto uni-
dentiﬁed phosphosite. The presence of a serine residue at
position n 3 of S601 (K
596ESKES
601) resembles the opti-
mal consensus recognition motif for CK1 (42), thereby
favouring S601 as the main phosphorylation site targeted
by CK1. Examination of the role of S601 revealed a phys-
iological importance of this site in the activity of AIB1 in
breast cancer cells, after demonstrating that mutation of
this aa negatively inﬂuenced the expression levels of the
E2-dependent pS2 genes. However, additional experi-
ments are required in order to elucidate the exact molec-
ular mechanism of the involvement of S601 in the
regulation of AIB1’s co-activation function.
Our data herein, reveal an association of CK1d with
ERa and AIB1, which can result in a complex formation
that enables CK1d to interact, phosphorylate and exert its
eﬀects by regulating the interaction between ERa and
AIB1 and thereby modulate the functions of these two
proteins.
AIB1 is a target for multiple signaling pathways and its
phosphorylation state is a determinant of its functionality
including degradation and interactions with other proteins
(17). Phosphorylation of AIB1 by diﬀerent kinases has
been associated with increased AIB1 degradation
(16,17); however, a recent report (10) identiﬁed aPKC as
the ﬁrst kinase able to stabilize AIB1 in cancer cells and
thereby enhance its activity. Based on our results, we pro-
pose a model where CK1d protects AIB1 from proteolysis,
as part of a balanced equilibrium in which kinases are
required to maintain a consistent protein level of AIB1
(Figure 8). However, aberrations in this balance towards
CK1d, as occurs in breast cancer, would be expected to
increase AIB1 levels, and therefore also the expression of
monoclonal antibody. Samples were probed for equal loading using a b-actin speciﬁc monoclonal antibody. (B) Quantitative analysis of AIB1 protein
levels is given as fold of control. (C) MCF7 cells were untransfected or transfected with 5nM CT siRNA or with 5nM CK1d siRNA for 72h. Where
indicated, cells were incubated with MG132 (5mM) for 6h and and then treated with E2 (100nM) for 45min. Cell extracts were immunoblotted with
AIB1 antibody. (D) Quantitative analysis of AIB1 protein levels with or without MG132 pre-treatment in the presence of E2. All data are repre-
sentative results from two independent experiments. (E) Fluorescence microscopy was performed on either untransfected MCF7 cells or cells
transfected with 5nM CK1d siRNA for 72h followed by the addition of E2 (100nM) for 45min. All cells were grown on coverslips, then ﬁxed
and stained as described in ‘Materials and Methods’ section.
Figure 5. CK1d associates with ERa and AIB1 in vivo and regulates
their interactions. (A) Lysates from untreated or E2-stimulated COS-1
cells were immunoprecipitated with CK1d or non-immune IgG fol-
lowed by immunoblotting with anti-ERa, anti-pS118/ERa and anti-
AIB1. (B) MCF7 cells (i) untransfected or (ii) transfected with a
(EYFP)-CK1d plasmid were stimulated with 100nM E2 for 30min
before precipitation with anti-AIB1 antibody. The interaction between
AIB1 and ERa was visualised by western blotting using an anti-ERa
antibody. Equal amounts of protein were added in both lanes.
Nucleic Acids Research,2009, Vol.37, No. 9 3119Figure 6. CK1d phosphorylates ERa and AIB1 in vitro.( A) Schematic representation of human ERa. AF: activator function. (B) In vitro kinase
assays were performed using puriﬁed recombinant human CK1d as source of enzyme and: (i) full-length recombinant human ERa, (ii) GST-
recombinant human ERa (aa 1–280) and (iii) GST-recombinant human ERa (aa 283–595), as substrates. (C) Schematic diagram of human AIB1
3120 Nucleic Acids Research, 2009, Vol. 37,No. 9with its known functional domains. bHLS/PAS: basic helix-loop-helix/Per-Arnt-Sim domain; RID: receptor interacting domain; CID: CBP/p300
interacting domain; HAT: histone acetyltransferase domain. The positions of all identiﬁed phosphorylation amino acids are indicated. (D) In vitro
kinase assays were performed using recombinant human CK1d as source of enzyme and as substrates: (i) puriﬁed full-length AIB1 and (ii) GST-
recombinant human AIB1 (aa 582–800). (E) CK1 phosphorylates one major residue of AIB1. GST–AIB1 aa 582–800 was phosphorylated in vitro by
the catalytic subunit of CK1 for the indicated times. Up to 1.6mol phosphate/mol protein were incorporated into the GST–AIB1 aa 582–800 fusion
protein. (F) Phosphorylation of GST–AIB1 fusion proteins by CK1d. In vitro kinase assays were performed using recombinant human CK1d as the
source of enzyme and: (i) GST–AIB1 aa 582–800 (wt), (ii) GST–AIB1 aa 582–800 (S664A), (iii) GST–AIB1 aa 582–800 (T714A), (iv) GST–AIB1 aa
582–800 (S715A), (v) GST–AIB1 aa 582–800 (S794A) and (vi) GST–AIB1 aa 582–800 (S601A), as substrates. Proteins were separated by SDS-PAGE
and the phosphorylated proteins were detected by autoradiography. Quantiﬁcation of phosphate incorporation of phosphorylated proteins was
measured by Cerenkov counting. Error bars represent SD of two experiments, each in triplicate. C: Coomasie. A: Autoradiogram.
Figure 8. A model for the regulation of ERa transcriptional activity, involving CK1d and AIB1. In the presence of E2, CK1d interacts with and
phosphorylates AIB1 predominantly at S601 and probably ERa at other site(s), inducing the formation of a complex between them that is required
for the complete transcriptional activity of ERa. Inhibition of CK1d-mediated phosphorylation, potentially alters the conformation of AIB1 and
promotes its proteasome-mediated degradation; subsequently, ERa protein levels are stabilized and ERa activity is decreased.
Figure 7. Functional role of CK1d-dependent phosphorylation of S601 in ERa-dependent transcription. MCF7 cells (2 10
5) were plated in 6-well
plates in phenol red-free DMEM containing 10% DSS. (A) Cells were co-transfected either with 1mg of: (i) pCMV-Flag-AIB1 and (EYFP)–CK1d
plasmids or, (ii) pCMV-Flag-AIB1/S601A and (EYFP)–CK1d plasmids for 24h. (B) Cells were transfected with 1mg of: (i) pCMV-Flag-AIB1 and,
(ii) pCMV-Flag-AIB1/S601A plasmid for 24h, followed by treatment with 1mM IC261 for 3h. Subsequently, all cells were treated or not (vehicle)
with E2 (10nM) for 24h. Cells were harvested and total RNA was extracted and used to synthesize cDNA by reverse transcription, as described in
‘Materials and Methods’ section. Gene expression of pS2 was measured by qRT-PCR. Error bars represent SD of two separate experiments, each in
triplicate (P<0.05).
Nucleic Acids Research,2009, Vol.37, No. 9 3121ERa-respondent target genes. These genes are critical to
breast cancer growth, as evidenced by the successes in
the use of anti-estrogens to treat breast cancer, so we spec-
ulate here that increases in their expression may be a
determinant of cancer progression and/or resistance to
anti-estrogens. It is interesting to note here that both the
receptor and its co-activator partner are subject to phos-
phorylation by the same kinase, introducing hierarchical,
sequential or simultaneous phosphorylation possibilities
in this dual regulatory pathway. However, using puriﬁed
substrates in the in vitro kinase assays suggests that CK1d
can interact with and phosphorylate both independently.
Our results, identifying a novel AIB1 phosphorylation
site (S601) that aﬀects the co-activation function of AIB1,
in conjunction with a new report which suggests that
tyrosine phosphorylation of AIB1 is also required for
its activity (43) demonstrate the importance of post-
translational modiﬁcations as an additional level of tran-
scriptional regulation. Generation of a phospho-speciﬁc
antibody against S601 in AIB1 is currently underway;
correlations between phosphorylated levels of AIB1at
S601 in breast cancer samples and clinical outcome para-
meters such as time to progression, overall survival and
clinical endocrine resistance, remain to be tested.
It has already been shown that ERa and AIB1 shuttle
between the cytoplasm and the nucleus (44,45). Phosphor-
ylation events induced by diﬀerent kinases occur in both
compartments inﬂuencing their functions, including stabi-
lity, mobility and activity (3,46–49) as per our proposed
model (Figure 8). In this report we identify CK1d, a pre-
dominantly cytoplasmic protein (50,51), as a novel kinase
implicated in the modulation of physiological aspects of
both ERa and AIB1.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We are indebted to Professors Bert W. O’Malley and
Simak Ali for their advice and critical reviews of this
work. We would also like to thank Dr Elena Kulinskaya
of the Statistical Advisory Service (Imperial College,
London) for helping with the statistical analyses of
our data.
FUNDING
Citrina Foundation, the family of Janet Booker and the
Hammersmith Hospitals’ Trustees’ Research Committee.
Conﬂict of interest statement. None declared.
REFERENCES
1. Cordera,F. and Jordan,V.C. (2006) Steroid receptors and their role
in the biology and control of breast cancer growth. Semin. Oncol.,
33, 631–641.
2. Ali,S. and Coombes,R.C. (2002) Endocrine-responsive breast cancer
and strategies for combating resistance. Nat. Rev. Cancer, 2,
101–112.
3. Lannigan,D.A. (2003) Estrogen receptor phosphorylation. Steroids,
68, 1–9.
4. Alarid,E.T., Bakopoulos,N. and Solodin,N. (1999) Proteasome-
mediated proteolysis of estrogen receptor: a novel component in
autologous down-regulation. Mol. Endocrinol., 13, 1522–1534.
5. Lonard,D.M., Nawaz,Z., Smith,C.L. and O’Malley,B.W. (2000)
The 26S proteasome is required for estrogen receptor-alpha and
coactivator turnover and for eﬃcient estrogen receptor-alpha
transactivation. Mol. Cell, 5, 939–948.
6. Nawaz,Z., Lonard,D.M., Dennis,A.P., Smith,C.L. and
O’Malley,B.W. (1999) Proteasome-dependent degradation of the
human estrogen receptor. Proc. Natl Acad. Sci. USA, 96,
1858–1862.
7. Preisler-Mashek,M.T., Solodin,N., Stark,B.L., Tyriver,M.K. and
Alarid,E.T. (2002) Ligand-speciﬁc regulation of proteasome-
mediated proteolysis of estrogen receptor-alpha. Am. J. Physiol.
Endocrinol. Metab., 282, E891–898.
8. Grisouard,J., Medunjanin,S., Hermani,A., Shukla,A. and Mayer,D.
(2007) Glycogen synthase kinase-3 protects estrogen receptor alpha
from proteasomal degradation and is required for full transcrip-
tional activity of the receptor. Mol. Endocrinol., 21, 2427–2439.
9. Valley,C.C., Metivier,R., Solodin,N.M., Fowler,A.M.,
Mashek,M.T., Hill,L. and Alarid,E.T. (2005) Diﬀerential regulation
of estrogen-inducible proteolysis and transcription by the estrogen
receptor alpha N terminus. Mol. Cell Biol., 25, 5417–5428.
10. Yi,P., Feng,Q., Amazit,L., Lonard,D.M., Tsai,S.Y., Tsai,M.J. and
O’Malley,B.W. (2008) Atypical protein kinase C regulates dual
pathways for degradation of the oncogenic coactivator SRC-3/
AIB1. Mol. Cell, 29, 465–476.
11. Anzick,S.L., Kononen,J., Walker,R.L., Azorsa,D.O., Tanner,M.M.,
Guan,X.Y., Sauter,G., Kallioniemi,O.P., Trent,J.M. and
Meltzer,P.S. (1997) AIB1, a steroid receptor coactivator ampliﬁed in
breast and ovarian cancer. Science, 277, 965–968.
12. Li,Q., Wrange,O. and Eriksson,P. (1997) The role of chromatin in
transcriptional regulation. Int. J. Biochem. Cell Biol., 29, 731–742.
13. Suen,C.S., Berrodin,T.J., Mastroeni,R., Cheskis,B.J., Lyttle,C.R.
and Frail,D.E. (1998) A transcriptional coactivator, steroid receptor
coactivator-3, selectively augments steroid receptor transcriptional
activity. J. Biol. Chem., 273, 27645–27653.
14. Torchia,J., Rose,D.W., Inostroza,J., Kamei,Y., Westin,S.,
Glass,C.K. and Rosenfeld,M.G. (1997) The transcriptional co-acti-
vator p/CIP binds CBP and mediates nuclear-receptor function.
Nature, 387, 677–684.
15. Shao,W., Keeton,E.K., McDonnell,D.P. and Brown,M. (2004)
Coactivator AIB1 links estrogen receptor transcriptional activity
and stability. Proc. Natl Acad. Sci. USA, 101, 11599–11604.
16. Gianni,M., Parrella,E., Raska,I. Jr., Gaillard,E., Nigro,E.A.,
Gaudon,C., Garattini,E. and Rochette-Egly,C. (2006) P38MAPK-
dependent phosphorylation and degradation of SRC-3/AIB1 and
RARalpha-mediated transcription. EMBO J., 25, 739–751.
17. Wu,R.C., Feng,Q., Lonard,D.M. and O’Malley,B.W. (2007) SRC-3
coactivator functional lifetime is regulated by a phospho-dependent
ubiquitin time clock. Cell, 129, 1125–1140.
18. Gross,S.D. and Anderson,R.A. (1998) Casein kinase I: spatial
organization and positioning of a multifunctional protein kinase
family. Cell Signal., 10, 699–711.
19. Knippschild,U., Gocht,A., Wolﬀ,S., Huber,N., Lohler,J. and
Stoter,M. (2005) The casein kinase 1 family: participation in mul-
tiple cellular processes in eukaryotes. Cell Signal., 17, 675–689.
20. Fuja,T.J., Lin,F., Osann,K.E. and Bryant,P.J. (2004) Somatic
mutations and altered expression of the candidate tumor suppres-
sors CSNK1 epsilon, DLG1, and EDD/hHYD in mammary ductal
carcinoma. Cancer Res., 64, 942–951.
21. von Blume,J., Knippschild,U., Dequiedt,F., Giamas,G., Beck,A.,
Auer,A., Van Lint,J., Adler,G. and Seuﬀerlein,T. (2007)
Phosphorylation at Ser244 by CK1 determines nuclear localization
and substrate targeting of PKD2. EMBO J., 26, 4619–4633.
22. Brockschmidt,C., Hirner,H., Huber,N., Eismann,T.,
Hillenbrand,A., Giamas,G., Radunsky,B., Ammerpohl,O.,
Bohm,B., Henne-Bruns,D. et al. (2008) Anti-apoptotic and growth-
stimulatory functions of CK1 delta and epsilon in ductal
3122 Nucleic Acids Research, 2009, Vol. 37,No. 9adenocarcinoma of the pancreas are inhibited by IC261 in vitro and
in vivo. Gut., 57, 799–806.
23. Giamas,G., Hirner,H., Shoshiashvili,L., Grothey,A., Gessert,S.,
Kuhl,M., Henne-Bruns,D., Vorgias,C.E. and Knippschild,U. (2007)
Phosphorylation of CK1delta: identiﬁcation of Ser370 as the major
phosphorylation site targeted by PKA in vitro and in vivo. Biochem.
J., 406, 389–398.
24. Stoter,M., Bamberger,A.M., Aslan,B., Kurth,M., Speidel,D.,
Loning,T., Frank,H.G., Kaufmann,P., Lohler,J., Henne-Bruns,D.
et al. (2005) Inhibition of casein kinase I delta alters mitotic spindle
formation and induces apoptosis in trophoblast cells. Oncogene, 24,
7964–7975.
25. Tsai,I.C., Woolf,M., Neklason,D.W., Branford,W.W., Yost,H.J.,
Burt,R.W. and Virshup,D.M. (2007) Disease-associated casein
kinase I delta mutation may promote adenomatous polyps forma-
tion via a Wnt/beta-catenin independent mechanism. Int. J. Cancer,
120, 1005–1012.
26. Wu,R.C., Qin,J., Yi,P., Wong,J., Tsai,S.Y., Tsai,M.J. and
O’Malley,B.W. (2004) Selective phosphorylations of the SRC-3/
AIB1 coactivator integrate genomic reponses to multiple cellular
signaling pathways. Mol. Cell, 15, 937–949.
27. Tora,L., White,J., Brou,C., Tasset,D., Webster,N., Scheer,E. and
Chambon,P. (1989) The human estrogen receptor has two inde-
pendent nonacidic transcriptional activation functions. Cell, 59,
477–487.
28. Balaguer,P., Francois,F., Comunale,F., Fenet,H., Boussioux,A.M.,
Pons,M., Nicolas,J.C. and Casellas,C. (1999) Reporter cell lines to
study the estrogenic eﬀects of xenoestrogens. Sci. Total Environ.,
233, 47–56.
29. Cheng,J., Zhang,C. and Shapiro,D.J. (2007) A functional serine 118
phosphorylation site in estrogen receptor-alpha is required for
down-regulation of gene expression by 17beta-estradiol and
4-hydroxytamoxifen. Endocrinology, 148, 4634–4641.
30. Behrend,L., Milne,D.M., Stoter,M., Deppert,W., Campbell,L.E.,
Meek,D.W. and Knippschild,U. (2000) IC261, a speciﬁc inhibitor of
the protein kinases casein kinase 1-delta and -epsilon, triggers the
mitotic checkpoint and induces p53-dependent postmitotic eﬀects.
Oncogene, 19, 5303–5313.
31. Chen,D., Riedl,T., Washbrook,E., Pace,P.E., Coombes,R.C.,
Egly,J.M. and Ali,S. (2000) Activation of estrogen receptor alpha
by S118 phosphorylation involves a ligand-dependent interaction
with TFIIH and participation of CDK7. Mol. Cell, 6, 127–137.
32. Chen,D., Washbrook,E., Sarwar,N., Bates,G.J., Pace,P.E.,
Thirunuvakkarasu,V., Taylor,J., Epstein,R.J., Fuller-Pace,F.V.,
Egly,J.M. et al. (2002) Phosphorylation of human estrogen receptor
alpha at serine 118 by two distinct signal transduction pathways
revealed by phosphorylation-speciﬁc antisera. Oncogene, 21,
4921–4931.
33. Kennelly,P.J. (2003) Archaeal protein kinases and protein phos-
phatases: insights from genomics and biochemistry. Biochem. J.,
370, 373–389.
34. Kostich,M., English,J., Madison,V., Gheyas,F., Wang,L., Qiu,P.,
Greene,J. and Laz,T.M. (2002) Human members of the eukaryotic
protein kinase family. Genome Biol., 3, RESEARCH0043.
35. Giamas,G., Stebbing,J., Vorgias,C.E. and Knippschild,U. (2007)
Protein kinases as targets for cancer treatment. Pharmacogenomics,
8, 1005–1016.
36. Medunjanin,S., Hermani,A., De Servi,B., Grisouard,J., Rincke,G.
and Mayer,D. (2005) Glycogen synthase kinase-3 interacts with and
phosphorylates estrogen receptor alpha and is involved in the reg-
ulation of receptor activity. J. Biol. Chem., 280, 33006–33014.
37. Reid,G., Hubner,M.R., Metivier,R., Brand,H., Denger,S.,
Manu,D., Beaudouin,J., Ellenberg,J. and Gannon,F. (2003) Cyclic,
proteasome-mediated turnover of unliganded and liganded ERalpha
on responsive promoters is an integral feature of estrogen signaling.
Mol. Cell, 11, 695–707.
38. Wijayaratne,A.L. and McDonnell,D.P. (2001) The human estrogen
receptor-alpha is a ubiquitinated protein whose stability is aﬀected
diﬀerentially by agonists, antagonists, and selective estrogen recep-
tor modulators. J. Biol. Chem., 276, 35684–35692.
39. Callige,M., Kieﬀer,I. and Richard-Foy,H. (2005) CSN5/Jab1
is involved in ligand-dependent degradation of estrogen receptor
{alpha} by the proteasome. Mol. Cell Biol., 25, 4349–4358.
40. Henrich,L.M., Smith,J.A., Kitt,D., Errington,T.M., Nguyen,B.,
Traish,A.M. and Lannigan,D.A. (2003) Extracellular signal-
regulated kinase 7, a regulator of hormone-dependent estrogen
receptor destruction. Mol. Cell Biol., 23, 5979–5988.
41. Marsaud,V., Gougelet,A., Maillard,S. and Renoir,J.M. (2003)
Various phosphorylation pathways, depending on agonist and
antagonist binding to endogenous estrogen receptor alpha
(ERalpha), diﬀerentially aﬀect ERalpha extractability, proteasome-
mediated stability, and transcriptional activity in human breast
cancer cells. Mol. Endocrinol., 17, 2013–2027.
42. Flotow,H., Graves,P.R., Wang,A.Q., Fiol,C.J., Roeske,R.W. and
Roach,P.J. (1990) Phosphate groups as substrate determinants for
casein kinase I action. J. Biol. Chem., 265, 14264–14269.
43. Oh,A.S., Lahusen,J.T., Chien,C.D., Fereshteh,M.P., Zhang,X.,
Dakshanamurthy,S., Xu,J., Kagan,B.L., Wellstein,A. and
Riegel,A.T. (2008) Tyrosine phosphorylation of the nuclear
receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and
is required for its activity in cancer cells. Mol. Cell Biol., 28,
6580–6593.
44. Amazit,L., Pasini,L., Szafran,A.T., Berno,V., Wu,R.C., Mielke,M.,
Jones,E.D., Mancini,M.G., Hinojos,C.A., O’Malley,B.W. et al.
(2007) Regulation of SRC-3 intercompartmental dynamics by
estrogen receptor and phosphorylation. Mol. Cell Biol., 27,
6913–6932.
45. Dauvois,S., White,R. and Parker,M.G. (1993) The antiestrogen ICI
182780 disrupts estrogen receptor nucleocytoplasmic shuttling.
J. Cell Sci., 106 (Pt 4), 1377–1388.
46. Lee,H. and Bai,W. (2002) Regulation of estrogen receptor nuclear
export by ligand-induced and p38-mediated receptor phosphoryla-
tion. Mol. Cell Biol., 22, 5835–5845.
47. Park,K.J., Krishnan,V., O’Malley,B.W., Yamamoto,Y. and
Gaynor,R.B. (2005) Formation of an IKKalpha-dependent tran-
scription complex is required for estrogen receptor-mediated gene
activation. Mol. Cell, 18, 71–82.
48. Wu,R.C., Smith,C.L. and O’Malley,B.W. (2005) Transcriptional
regulation by steroid receptor coactivator phosphorylation. Endocr.
Rev., 26, 393–399.
49. Zheng,F.F., Wu,R.C., Smith,C.L. and O’Malley,B.W. (2005) Rapid
estrogen-induced phosphorylation of the SRC-3 coactivator occurs
in an extranuclear complex containing estrogen receptor. Mol. Cell
Biol., 25, 8273–8284.
50. Behrend,L., Stoter,M., Kurth,M., Rutter,G., Heukeshoven,J.,
Deppert,W. and Knippschild,U. (2000) Interaction of casein kinase
1 delta (CK1delta) with post-Golgi structures, microtubules and the
spindle apparatus. Eur. J. Cell Biol., 79, 240–251.
51. Milne,D.M., Looby,P. and Meek,D.W. (2001) Catalytic
activity of protein kinase CK1 delta (casein kinase 1delta) is
essential for its normal subcellular localization. Exp. Cell Res., 263,
43–54.
Nucleic Acids Research,2009, Vol.37, No. 9 3123